Phase II trials - endpoints, when to randomize

被引：0
|
作者：
Zee, Benny [1 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2007年 / 2卷 / 08期
关键词：
D O I：
10.1097/01.JTO.0000283066.47583.94
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S291 / S291
页数：1
相关论文
共 50 条
  • [31] Exact two-stage designs for phase II activity trials with rank-based endpoints
    Wilding, Gregory E.
    Shan, Guogen
    Hutson, Alan D.
    CONTEMPORARY CLINICAL TRIALS, 2012, 33 (02) : 332 - 341
  • [32] BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints
    Zhou, Heng
    Lee, J. Jack
    Yuan, Ying
    STATISTICS IN MEDICINE, 2017, 36 (21) : 3302 - 3314
  • [33] Randomize the Running Function When It Is Disclosed
    Li, Yonggang
    Bao, Yu
    Chung, Yeh-Ching
    IEEE TRANSACTIONS ON COMPUTERS, 2024, 73 (06) : 1516 - 1530
  • [34] The use of historical priors to improve the efficiency of phase II clinical trials with time-to-event endpoints
    Richard Jackson
    Trevor Cox
    Catrin Tudur-Smith
    Trials, 14 (Suppl 1)
  • [35] Surrogate endpoints in clinical trials: when is good...good enough?
    Schnuck, Jamie Olapo
    Chauhan, Sardar Shahmir B.
    Sham, Jonathan G.
    HEPATOBILIARY SURGERY AND NUTRITION, 2024, 13 (06) : 1062 - 1064
  • [36] Alternate Endpoints for Screening Phase II Studies
    Dhani, Neesha
    Tu, Dongsheng
    Sargent, Daniel J.
    Seymour, Lesley
    Moore, Malcolm J.
    CLINICAL CANCER RESEARCH, 2009, 15 (06) : 1873 - 1882
  • [37] ASSESSING CLINICAL-TRIALS - WHY RANDOMIZE
    GORE, SM
    BRITISH MEDICAL JOURNAL, 1981, 282 (6280): : 1958 - 1960
  • [38] Choice theory when agents can randomize
    Stoye, Joerg
    JOURNAL OF ECONOMIC THEORY, 2015, 155 : 131 - 151
  • [39] Secondary endpoints in the phase Ill pivotal trials of tapentadol ER
    Schmidt, P.
    JOURNAL OF PAIN, 2016, 17 (04): : S85 - S86
  • [40] Primary endpoints of phase III trials for older patients with cancer
    Mizutani, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S1187 - S1187
12345